Epigenetic Diagnostics Market Size, Share, Opportunities, And Trends By Product (Reagents, Kits, Instruments, Enzymes, Services), By Application (Oncology, Non-Oncology), By Technology (DNA Methylation, Histone Methylation, Histone Acetylation, Large Non - Coding RNA, Microrna Modification, Chromatin Structures), And By Geography - Forecasts From 2023 To 2028

  • Published : Aug 2023
  • Report Code : KSI061615892
  • Pages : 148

The epigenetic diagnostics market was valued at US$12.070 billion in 2021.

The epigenetic diagnostics market is predicted to grow steadily. Epigenetics diagnosis is the study of genetic, cellular, and physical characteristic changes, as well as developmental biology that is influenced by the external environment. This has an impact on genes and cells' capacity to read genes independently in genotype. The underlying DNA and RNA sequence is unaffected, and the epigenetic modifications affect the phenotype of the organism rather than its genotype. Since epigenetic modifications are dynamic and adapt to the environment, they are crucial for development.

Epigenetic Diagnostics market growth drivers

The significant growth in epigenetics diagnostics market is mostly related to rising investments, funding, and regulatory approvals for epigenetics research and development, expanding epigenetic applications in drug discovery and development, and rising genome sequencing costs. Epigenetics has demonstrated its potential for use in non-oncology illnesses, opening up enormous commercial development prospects. Numerous malignancies, Cardiovascular Disorders (CVDs), reproductive issues, autoimmune disorders, and conditions that impair cognitive function may be caused directly or indirectly by epigenetic processes.

The increasing influence of external stimuli

The causal agents, such as heavy metals, pesticides, cigarette smoke, hormones, radiation, viruses, environmental variables, and important nutrients, can have an impact on how these epigenetic pathways work. One of the key drivers of this epigenetics diagnostics market growth is due to the rising demand for such kits and assays and the increased awareness of the value of epigenetic testing. For instance, as per the WHO report released in April 2023, the weighted average health GERD as% of GDP grew the highest in high-income countries (0.25%) compared to the previous analysis (0.21%),

DNA methylation shows significant growth potential

The DNA methylation procedure, which is used to prepare DNA for methylation analysis, involves the biochemical and enzymatic treatment of DNA by methylation-sensitive enzymes. The DNA methylation approach holds significant potential for elucidating the physiological mechanisms behind complex illnesses and creating personalised treatments. More often, genome-wide assessments of locus-specific DNA methylation are now achievable because of technological improvements. Histone acetylation is therapeutically useful in treating diseases such as solid tumours, inflammation, leukaemia, and viral infection.

The growing use of epigenetics diagnostic reagents

The significant epigenetics diagnostics market share is mostly due to the extensive use of reagents in epigenetic research investigations. Histone and DNA modifiers are the two primary types of reagents utilised in epigenetics. Epigenetics is the study of enduring, potentially reversible changes in gene expression that occur without permanently changing the DNA sequence but still pass from one generation to the next. Genes that are epigenetically regulated can be activated or silenced without any alterations to the DNA. The three primary epigenetic mechanisms that have been thoroughly studied are DNA methylation, RNA regulation, and histone modification.

The North American epigenetics diagnostics market is anticipated to grow significantly.

A significant portion of North American epigenetics diagnostics market share is mostly ascribed to government assistance and the existence of big businesses. Other elements that contribute to the epigenetics diagnostics market growth in the area include strong R&D spending, modern medical infrastructure, and high public awareness. Additionally, the high frequency of chronic illnesses and rising epigenetics diagnostics market participant investment in the advancement of epigenetics will foster regional growth. For example, in November 2021, Chroma Medicine, Inc., a cutting-edge genomic medicine company that invented epigenetic editing, launched with USD 125 million in financing to cure a range of diseases and develop into the most widely utilised technique for gene regulation.

Asia Pacific is predicted to be the second-largest growing market

The Asia Pacific epigenetics diagnostics market is anticipated to increase significantly due to rising government expenditure on R&D initiatives and an increase in cancer occurrences. For instance, in 2022, about one in ten deaths in the area occurred in the WHO South-East Asia area, which reported 1.4 million cancer-related fatalities and over 2.2 million new cases. 10.6% of all cancer-related deaths were due to lung cancer, with the next leading causes being breast cancer (9.4%), cervical cancer (8%), liver cancer (6.6%), and oral cavity cancer (6.4%). During the anticipated period, regional epigenetics diagnostics market growth will be aided by the expanding use of epigenetics in emerging nations.

Epigenetics Diagnostics market opportunity

New possibilities for the development of epigenetic treatments are emerging as a result of the discovery of epigenetic alterations as disease-causing factors. Epigenetic biomarkers can be used in precision medicine to identify people who are prone to acquire certain diseases or who are likely to respond favourably to particular therapies. Precision medicine strategies, which attempt to customise therapies to each patient's unique needs, are being developed as a result of this. Research and development spending is rising as the potential of epigenetics to enhance human health which becomes more widely understood.

Market Key Developments

  • In January 2023, Avida Biomed, a business that creates target enrichment processes for clinical researchers using NGS techniques to examine tumours, has been acquired by Agilent Technologies, Inc.
  • In February 2022, in a trial for solid tumour cancer funded by the National Cancer Institute (NCI), a division of the National Institutes of Health, Zenith Epigenetics Ltd. reported administering ZEN-3694 (a BET inhibitor) along with Bristol Myers Squibb's PD-1 immune checkpoint inhibitor OPDIVO and YERVOY on the first patient.
  • In February 2022, to showcase the benefits and effectiveness of Dovetail Genomics' proximity ligation-based next-generation sequencing (NGS) library prep solutions on Element's AVITI System, Element Biosciences, Inc., the creator of a novel and innovative DNA sequencing technology, partnered with the company.


  • By Product
    • Reagents
    • Kits
    • Instruments
    • Enzymes
    • Services
  • By Application
    • Oncology
    • Non-Oncology
  • By Technology
    • DNA Methylation
    • Histone Methylation
    • Histone Acetylation
    • Large Non - Coding RNA
    • Microrna Modification
    • Chromatin Structures
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • United Kingdom
      • Germany
      • France
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Israel
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Indonesia
      • Thailand
      • Others


1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline


2.1. Research Data

2.2. Assumptions


3.1. Research Highlights


4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis


5.1. Introduction

5.2. Reagents

5.3. Kits

5.4. Instruments

5.5. Enzymes

5.6. Services


6.1. Introduction

6.2. Oncology

6.3. Non-Oncology


7.1. Introduction

7.2. DNA Methylation

7.3. Histone Methylation

7.4. Histone Acetylation

7.5. Large Non - Coding RNA

7.6. Microrna Modification

7.7. Chromatin Structures


8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others


9.1. Major Players and Strategy Analysis

9.2. Emerging Players and Market Lucrativeness

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix


10.1. Roche Diagnostics

10.2. Thermo Fisher Scientific, Inc.

10.3. Eisai Co. Ltd.

10.4. Novartis AG

10.5. Element Biosciences, Inc.

10.6. Dovetail Genomics LLC.

10.7. Illumina, Inc.

10.8. Abcam plc.

Roche Diagnostics

Thermo Fisher Scientific, Inc.

Eisai Co. Ltd.

Novartis AG

Element Biosciences, Inc.

Dovetail Genomics LLC.

Illumina, Inc.

Abcam plc.